271 related articles for article (PubMed ID: 23593225)
1. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.
Keeling KM; Wang D; Dai Y; Murugesan S; Chenna B; Clark J; Belakhov V; Kandasamy J; Velu SE; Baasov T; Bedwell DM
PLoS One; 2013; 8(4):e60478. PubMed ID: 23593225
[TBL] [Abstract][Full Text] [Related]
2. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
[TBL] [Abstract][Full Text] [Related]
3. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
[TBL] [Abstract][Full Text] [Related]
4. Effects of gentamicin inducing readthrough premature stop Codons: A study of alpha-L-iduronidase nonsense variants in COS-7 Cells.
Ngiwsara L; Sawangareetrakul P; Wattanasirichaigoon D; Tim-Aroon T; Dejkhamron P; Champattanachai V; Ketudat-Cairns JR; Svasti J
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):147-154. PubMed ID: 36332477
[TBL] [Abstract][Full Text] [Related]
5. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
[TBL] [Abstract][Full Text] [Related]
6. Ataluren suppresses a premature termination codon in an MPS I-H mouse.
Wang D; Xue X; Gunn G; Du M; Siddiqui A; Weetall M; Keeling KM
J Mol Med (Berl); 2022 Aug; 100(8):1223-1235. PubMed ID: 35857082
[TBL] [Abstract][Full Text] [Related]
7. Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations.
Huang L; Low A; Damle SS; Keenan MM; Kuntz S; Murray SF; Monia BP; Guo S
Genome Biol; 2018 Jan; 19(1):4. PubMed ID: 29334995
[TBL] [Abstract][Full Text] [Related]
8. Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.
Keeling KM
Diseases; 2016 Dec; 4(4):. PubMed ID: 28367323
[TBL] [Abstract][Full Text] [Related]
9. Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes.
Adachi H; Pan Y; He X; Chen JL; Klein B; Platenburg G; Morais P; Boutz P; Yu YT
Mol Cell; 2023 Feb; 83(4):637-651.e9. PubMed ID: 36764303
[TBL] [Abstract][Full Text] [Related]
10. Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome).
Siddiqui A; Dundar H; Sharma J; Kaczmarczyk A; Echols J; Dai Y; Sun CR; Du M; Liu Z; Zhao R; Wood T; Sanders S; Rasmussen L; Bostwick JR; Augelli-Szafran C; Suto M; Rowe SM; Bedwell DM; Keeling KM
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901952
[TBL] [Abstract][Full Text] [Related]
11. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
[TBL] [Abstract][Full Text] [Related]
12. A regulated NMD mouse model supports NMD inhibition as a viable therapeutic option to treat genetic diseases.
Echols J; Siddiqui A; Dai Y; Havasi V; Sun R; Kaczmarczyk A; Keeling KM
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32737261
[TBL] [Abstract][Full Text] [Related]
13. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
[TBL] [Abstract][Full Text] [Related]
14. Arginine CGA codons as a source of nonsense mutations: a possible role in multivariant gene expression, control of mRNA quality, and aging.
Romanov GA; Sukhoverov VS
Mol Genet Genomics; 2017 Oct; 292(5):1013-1026. PubMed ID: 28523359
[TBL] [Abstract][Full Text] [Related]
15. Nonsense suppression therapies in ocular genetic diseases.
Wang X; Gregory-Evans CY
Cell Mol Life Sci; 2015 May; 72(10):1931-8. PubMed ID: 25651836
[TBL] [Abstract][Full Text] [Related]
16. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations.
McHugh DR; Cotton CU; Hodges CA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210
[TBL] [Abstract][Full Text] [Related]
17. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
Keeling KM; Bedwell DM
Wiley Interdiscip Rev RNA; 2011; 2(6):837-52. PubMed ID: 21976286
[TBL] [Abstract][Full Text] [Related]
18. Nonsense mutations in the rhodopsin gene that give rise to mild phenotypes trigger mRNA degradation in human cells by nonsense-mediated decay.
Roman-Sanchez R; Wensel TG; Wilson JH
Exp Eye Res; 2016 Apr; 145():444-449. PubMed ID: 26416182
[TBL] [Abstract][Full Text] [Related]
19. Nonsense-mediated mRNA decay: inter-individual variability and human disease.
Nguyen LS; Wilkinson MF; Gecz J
Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():175-86. PubMed ID: 24239855
[TBL] [Abstract][Full Text] [Related]
20. mRNAs containing NMD-competent premature termination codons are stabilized and translated under UPF1 depletion.
Kim WK; Yun S; Kwon Y; You KT; Shin N; Kim J; Kim H
Sci Rep; 2017 Nov; 7(1):15833. PubMed ID: 29158530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
